| Field | Specification |
|---|---|
| Target | |
| Alternative names | ACD22-VCMMAE, DCDT2980S, FCU2803, RG-7593, RO5541072-000 |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Expression system | |
| Purity | |
| Purification | |
| Form | Liquid |
| Storage | |
| Storage buffer | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
Pinatuzumab (HB011066) is a research-grade recombinant antibody targeting CD22. Produced in mammalian cells with native-like glycosylation. Highlights- Research Grade — For PK/PD studies, assay development, and ADA research.
- Native Glycosylation — Mammalian expression ensures native-like patterns.
Specifications
| Host Species | Humanized |
|---|---|
| Species Reactivity | Human |
| Clonality | Monoclonal |
| Isotype | IgG1, kappa |
| Target | Sialic acid-binding Ig-like lectin 2, Siglec-2, CD22, T-cell surface antigen Leu-14, BL-CAM, SIGLEC2, B-lymphocyte cell adhesion molecule, B-cell receptor CD22 |
| Purification | Protein A/G purified from cell culture supernatant. |
| Purity | >95% purity as determined by SDS-PAGE. |
| Form | Liquid |
| Storage Buffer | 0.01M PBS, pH 7.4. |
| Expression System | Mammalian Cells |
| UniProt | P20273 |
Validated Applications
| Application |
|---|
| ELISA |
| Flow Cytometry |
| Functional Assay |
| In Vivo Studies |
Scientific Background
B-cell receptor CD22 is a ~95 kDa protein. Most highly expressed siglec (sialic acid-binding immunoglobulin-like lectin) on B-cells that plays a role in various aspects of B-cell biology including differentiation, antigen presentation, and trafficking to bone marrow. Binds to alpha 2,6-linked sialic acid residues of surface molecules such as CD22 itself, CD45 and IgM in a cis configuration. Can also bind to ligands on other cells as an adhesion molecule in a trans configuration. Acts as an inhibitory coreceptor on the surface of B-cells and inhibits B-cell receptor induced signaling, characterized by inhibition of the calcium mobilization and cellular activation. Mechanistically, the immunoreceptor tyrosine-based inhibitory motif domain is phosphorylated by the Src kinase LYN, which in turn leads to the recruitment of the protein tyrosine phosphatase 1/PTPN6, leading to the negative regulation of BCR signaling. CD22 is the therapeutic target of inotuzumab ozogamicin (Besponsa).
Reactivity
This antibody shows reactivity with Human.
Safety & Handling
Customization & Add-ons: Can't find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
1. Meyer, SJ. et al. (2021) Journal of immunology (Baltimore, Md. : 1950) 207, 1018-1032. PMID: 34330755
2. Law, CL. et al. (1996) The Journal of experimental medicine 183, 547-60. PMID: 8627166
3. Ramya, TN. et al. (2010) Molecular & cellular proteomics : MCP 9, 1339-51. PMID: 20172905
4. Séïté, JF. et al. (2010) Blood 116, 1698-704. PMID: 20516366
